Haemodynamic effects of rivaroxaban
Research type
Research Study
Full title
Flow mediated dilatation measurement in patients taking rivaroxaban for acute thrombosis
IRAS ID
171510
Contact name
Kathryn Lang
Contact email
Sponsor organisation
King's College Hospital NHS Foundation Trust
Duration of Study in the UK
0 years, 7 months, 4 days
Research summary
As clinical experience of the novel oral anticoagulant rivaroxaban grows, it is noted that a significant proportion of patients, up to one in ten, will experience either dizziness or hypotension subsequent to starting therapy. This can be severe enough to warrant a change in treatment and as yet, there is no understanding of the mechanism.
As a pilot project to better understand the phenomenon, we propose a research project to investigate whether there are demonstrable haemodynamic alterations in patients taking rivaroxaban.
Since in vivo measurement of haemodynamic alterations tends to require invasive procedures, we propose a simple measurement of flow mediated dilatation to assess endothelial function in patients before they start treatment with rivaroxaban and after one week.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
15/EM/0330
Date of REC Opinion
23 Jul 2015
REC opinion
Further Information Favourable Opinion